Journal
CHEMMEDCHEM
Volume 10, Issue 11, Pages 1821-1836Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201500301
Keywords
human African trypanosomiasis (HAT); medicinal chemistry; N-myristoyltransferase; structure-based drug design; Trypanosoma brucei
Categories
Funding
- Wellcome Trust [077705, 094090, WT083481]
Ask authors/readers for more resources
The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically and biologically as a potential drug target for human African trypanosomiasis. We previously reported the development of some very potent compounds based around a pyrazole sulfonamide series, derived from a high-throughput screen. Herein we describe work around thiazolidinone and benzomorpholine scaffolds that were also identified in the screen. An X-ray crystal structure of the thiazolidinone hit in Leishmania major NMT showed the compound bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X-ray crystallography/structure-based design approach, the benzomorpholinone series was further optimised, increasing activity against T.brucei NMT by >1000-fold. A series of trypanocidal compounds were identified with suitable in vitro DMPK properties, including CNS exposure for further development. Further work is required to increase selectivity over the human NMT isoform and activity against T.brucei.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available